Ibopamine does not affect insulin resistance in patients with type I diabetes.
Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t.i.d.) treatment. Metabolic control and daily insulin dose did not change in any patient during the study. The insulin-mediated glucose uptake during the clamp studies showed no variation after placebo or ibopamine therapy. Total cholesterol, HDL-cholesterol and triglycerides concentrations remained unchanged. This study clearly suggests that ibopamine administered at a daily dose of 300 mg for 3 weeks presents a metabolic safety in type I diabetic patients.
Benzi
L
L
Chair of Metabolic Disease, University of Pisa, Italy.
Sabino
F
F
Ciccarone
A M
AM
Cecchetti
P
P
Di Cianni
G
G
Cicchetti
V
V
Navalesi
R
R
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002316:Cardiotonic Agents; D003846:Deoxyepinephrine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications*; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D014665:Vasodilator Agents
D001786:Blood Glucose; D002316:Cardiotonic Agents; D007328:Insulin; D014665:Vasodilator Agents; C023487:ibopamine; D003846:Deoxyepinephrine